# Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors: an analysis of the UK Biobank

Maxine Sun<sup>1,2,3</sup>, Marie-Christyne Cyr<sup>1,2</sup>, Johanna Sandoval<sup>1,2</sup>, Louis-Philippe Lemieux Perreault<sup>1,2</sup>, Lambert Busque<sup>3,4</sup>, Jean-Claude Tardif<sup>1,3</sup>, Marie-Pierre Dubé<sup>1,2,3</sup>

<sup>1</sup>Montreal Heart Institute, Montreal, Canada

<sup>2</sup>Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada <sup>3</sup>Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Canada

<sup>4</sup>Hôpital Maisonneuve-Rosemont

# **Corresponding author:**

Marie-Pierre Dubé, PhD Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre 5000 Belanger Street, Montreal, QC, H1T 1C8 Canada Tel: +514 376 3330; Fax: + 514 593 2521 Email: marie-pierre.dube@umontreal.ca

# **Disclosures/Conflicts of interest:**

M-P.D. has received personal fees and reports minor equity interest in Dalcor Pharmaceuticals. M-P.D. has a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor Pharmaceuticals, no royalties received; and a patent Methods for using low dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute.

J-C.T. reports research grants from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, and RegenXBio; honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm and Pfizer; minor equity interest from Dalcor Pharmaceuticals; and authorship on a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor Pharmaceuticals, no royalties received; a pending patent Early administration of low-dose colchicine after myocardial infarction, and a patent Methods for using low-dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute (J-C.T. has waived his rights in the colchicine patents). Other authors have nothing to declare.

# Funding

M.S. was funded by a doctorate scholarship from the Fonds de Recherche du Québec -Santé (FRQS). M-P.D. and J-C.T. hold Canada Research Chairs. This project was funded in part by the Health Collaboration Acceleration Fund (FACS) from the Government of Quebec (J-C.T. principal investigator and M-P.D. co-principal investigator).

# Acknowledgements

We thank the UK Biobank for providing the data under Application Number 20168.

#### 1 ABSTRACT

2

3 Cancer survivors are at an increased risk of cardiovascular disease (CVD) compared to the general population. Here, we evaluated the impact of somatic mosaic chromosomal 4 alterations (mCAs) on death of CVD causes, coronary artery disease (CAD) causes, 5 6 from cancer, and of any cause in patients with a cancer diagnosis within the UK Biobank (n=48 919). mCAs were derived from DNA genotyping array intensity data and long-7 range chromosomal phase inference from participants. Overall, 10 070 individuals 8 9 (20.6%) carried ≥1 mCA clone. In adjusted analyses, mCA was associated with an increased risk of death of CAD causes (hazard ratio [HR]: 1.37, 95% confidence interval 10 [CI]: 1.09-1.71, P=0.006), from cancer (HR: 1.06, 95% CI: 1.00-1.11, P=0.041), and 11 12 death of any cause (HR: 1.07, 95% CI: 1.02-1.12, P=0.005). Among cancer survivors, 13 carriers of any mCA are at an increased risk of death of CAD causes and of any cause as compared to non-carriers. 14

15

16 Keywords: clonal hematopoiesis, CHIP, mosaic chromosomal alterations,
17 cardiovascular mortality, UK Biobank

18

#### 1 INTRODUCTION

2 The number of survivors of cancer is growing worldwide due to the ageing populations and improvements in early cancer detection and treatment modalities.<sup>1</sup> It is estimated 3 that over 26 million people in the United States alone will be living with a history of 4 cancer by the year 2040.<sup>2,3</sup> Among cancer survivors, a pressing clinical problem is their 5 increased predisposition to cardiovascular disease (CVD)<sup>4,5</sup> and treatment-related 6 cardiac dysfunction<sup>6,7</sup>. Currently, there are no guideline recommendations with respect 7 8 to CVD screening for patients with cancer, possibly stemming from the lack of CVD-9 related markers that can better risk-stratify cancer patients beyond existing cardiovascular risk factors for the general population.<sup>8</sup> The identification and 10 development of biomarkers that can eventually be used towards a risk assessment tool 11 for the purpose of discriminating patients diagnosed with cancer who are at a higher risk 12 of CVD may be useful.<sup>8</sup> 13

14 Clonal Hematopoiesis (CH) refers to a population of cells derived from a mutated multipotent stem/progenitor cell occurring in the context of aging.<sup>9</sup> CH can be caused by 15 somatic mutation in driver genes<sup>10-14</sup> called clonal hematopoiesis of indeterminate 16 potential (CHIP)<sup>15</sup>, or by somatic mosaic chromosomal alterations (mCA).<sup>16-20</sup> 17 Previously, CHIP has been associated with a greater burden of atherosclerotic vessel 18 disease<sup>21</sup>, a higher risk of myocardial infarction<sup>22,23</sup>, inflammatory response<sup>24</sup>, and death 19 of any cause<sup>11,12</sup>. The presence of CHIP has also been associated with treatment-20 related adverse outcomes in cancer survivors.<sup>25,26</sup> 21

22 Somatic mCAs correspond to large chromosomal gains, loss, or copy neutral losses of 23 heterozygosity which can affect autosomes or sexual chromosomes.<sup>27</sup> The most

prevalent mCA is the loss of the Y chromosome in aging men.<sup>28</sup> Mosaic loss of the Y
 chromosome has been associated with all-cause mortality<sup>29,30</sup>, Alzheimer's disease<sup>31</sup>,
 autoimmune disease<sup>32</sup>, diabetes<sup>29</sup>, and cardiovascular events<sup>33</sup>.

Given the links between CH and CVD in the normal aging population, and the paucity of data in cancer survivors, we sought to evaluate the impact of mCAs on the risk of death from CVD causes, from cancer, and of any cause among cancer survivors at risk of CVD by relying on DNA genotyping array intensity data and long-range chromosomal phase information inferred from participants of the UK Biobank. Our hypothesis was that carriers of any mCA would be at higher risk of death from CVD causes compared to their mCA non-carriers.

#### 1 Results

#### 2 Baseline characteristics and mCA prevalence

Overall, 48 919 participants were diagnosed with bladder, larynx, corpus uteri, prostate,
rectal, breast, kidney, non-Hodgkin lymphoma, melanoma, or lung cancer within the UK
Biobank (Table 1). The mean age at study entry was 60 years old (median 62,
interquartile range [IQR]: 56-65). Forty-six percent (45.8%) were men and 39.6%
previously smoked.

The presence of at least one mCA clone was observed in 20.6% (10 070/48 919) of 8 9 patients (Suppl. Materials, sFigure 1A). Of those, 2 432 were autosomal carriers and 1 910 had mCA in ≥10% of peripheral leukocytes, defined as an expanded mCA clone. 10 Whereas most carriers had only one mCA, 812 individuals carried ≥2 non-overlapping 11 mCAs. In general, those with mCA were older (median 64 vs. 61 years), where the 12 prevalence of mCA increased with increasing age categories: 4.8% among those aged 13 <49 years old, 12.1% for those aged 50-59 years old, 26.4% for those aged 60-69 years 14 old, and 30.4% for those aged  $\geq$ 70 years old (Suppl. Materials, sFigure 1B). 15 16 Expectedly, 73.6% of patients with mCA were men, likely because the majority of mCA carriers was due to loss of the Y chromosome (n=6 558). In comparison, mCA due to 17 loss of the X chromosome was observed in 1 641 patients (16.3%). Amongst patients 18 older than 65 years old, the prevalence of mCA according to cancer types was the 19 20 lowest for breast cancer (14%) and the highest for larynx cancer (43%, Suppl. 21 Materials, sFigure 1C).

22 mCA and the risk of death of CVD causes, coronary artery disease (CAD) causes, from 23 cancer, and any cause

medRxiv preprint doi: https://doi.org/10.1101/2022.08.20.22279019; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

In adjusted Cox regression analyses, mCA was associated with an increased risk of 1 2 death of coronary artery disease (CAD) causes (hazard ratio [HR]: 1.37, 95% confidence interval [CI]: 1.09-1.71, P=0.006), death from cancer (HR: 1.06, 95% CI: 3 1.00-1.11, P=0.041), and death of any cause (HR: 1.07, 95% CI: 1.02-1.12, P=0.005, 4 5 Figure 1). These effects were maintained after the additional adjustment for 6 hypertension and body-mass index in sensitivity analyses (Suppl. Materials, sTable 1). 7 Sub-analyses according to smoking status showed that mCAs were associated with significantly higher risks of death of CVD causes (smoking-by-mCA P<sub>interaction</sub>=0.044), 8 9 and death of any cause (smoking-by-mCA P<sub>interaction</sub>=0.011), but not with death of CAD-10 causes (smoking-by-mCA P<sub>interaction</sub>=0.50) or with death from cancer (smoking-by-mCA 11 Suppl. Materials, sTable 2). In sub-analyses  $P_{interaction}=0.266,$ considering 12 chemotherapy, chemotherapy-by-mCA interaction terms were not significant for any of 13 the primary endpoints (all *P*<sub>interaction</sub>≥0.05, **Suppl. Materials, sTable 3**).

14 Different types of mCAs had different effects on the study endpoints. Notably, autosomal 15 mCAs were associated with death of CVD causes (HR: 1.35, 95% CI: 1.04-1.75, 16 P=0.023), with death from cancer (HR: 1.14, 95% CI: 1.04-1.24, P=0.004), as well as 17 with death of any cause (HR: 1.14, 95% CI: 1.06, 1.24, P<0.001, Suppl. Materials, sTable 4). mCA due to loss of the X chromosome was associated with death of CAD 18 19 causes (HR: 2.02, 95% CI: 1.16, 3.54, P=0.013, Suppl. Materials, sTable 5), and mCA due to loss of the Y chromosome was associated with death of any cause (HR: 1.08, 20 95% CI: 1.02-1.14, P=0.009, Suppl. Materials, sTable 6). Expanded mCAs taken 21 22 individually had no statistically significant impact on the primary endpoints (Suppl. Materials, sTable 7). When considering the study population of 479 435 participants 23 with, and without a history of any cancer, the interaction terms between cancer and 24

mCA were significant for death from cancer (*P*<sub>interaction</sub><0.001) and death of any cause</li>
(*P*<sub>interaction</sub><0.001, **Suppl. Materials, sTable 8**). On the other hand, the interaction terms
between cancer status and mCA for death of CVD causes and CAD causes were not
statistically significant (**Suppl. Materials, sTable 8**).

5 mCA and the risk of death of CVD causes, CAD causes, from cancer, and any cause 6 according to cancer site

In multivariable analyses where the effect of mCA was assessed in subgroups according 7 to cancer type, we found that carriers of mCAs diagnosed with kidney cancer had an 8 increased risk of death of CVD causes (HR: 2.03, 95% CI: 1.11-3.72, P=0.022) and CAD 9 causes (HR: 3.57, 95% CI: 1.44-8.84, P=0.006, Suppl. Materials, sTables 9 & 10) 10 11 compared to their mCA non-carriers counterparts diagnosed with kidney cancer. Women diagnosed with breast cancer who carried a mCA also had a higher risk of death of CAD 12 causes (HR: 2.46, 95% CI: 1.23-4.92, P=0.011), mCA had no significant impact on 13 deaths from cancer in either cancer type (Suppl. Materials, sTable 11). Women carriers 14 of mCA diagnosed with corpus uteri cancer had an increased risk of death of any cause 15 16 (HR: 1.35, 95% CI: 1.01-1.80, *P*=0.042, **Suppl. Materials, sTable 12**).

17 mCA and the risk of incident CV endpoints (exploratory analyses)

In the overall cohort of cancer survivors (n=48 919), carriers of mCA had a higher risk of incident ST-elevation myocardial infarction (STEMI) (HR: 1.19, 95% CI: 1.03-1.37, P=0.022) and peripheral vascular disease (HR: 1.17, 95% CI: 1.04-1.31, P=0.007, **Figure 2**) than mCA non-carriers. Amongst those aged 65 years and above, carriers of mCA showed a higher risk of incident STEMI (HR: 1.23, 95% CI: 1.02-1.49, P=0.034), non-STEMI (HR: 1.20, 95% CI: 1.03-1.40, P=0.020), stable angina (HR: 1.20, 95% CI: 1.00-1.44, P=0.047), intracerebral hemorrhage (HR: 1.22, 95% CI: 1.01-1.48, P=0.038),

- 1 subarachnoid hemorrhage (HR: 1.23, 95% CI: 1.01-1.50, P=0.040), and peripheral
- 2 vascular disease (HR: 1.20, 95% CI: 1.03-1.39, *P*=0.017, **Suppl. Materials, sTable 13**).

#### 1 DISCUSSION

2

Here, we assessed the impact of somatic mCAs, a subtype of CH, on the risks of death 3 of CVD causes, CAD causes, from cancer, and death of any cause focusing exclusively 4 5 on individuals diagnosed with one of 10 cancer types known to have the highest reported rates of CVD deaths<sup>34</sup>. First, we found that carriers of mCAs had an increased 6 7 risk of death of CAD causes, from cancer, and of any cause. Some of the associations were more impactful in mCA subtypes, notably autosomal mCAs were associated with 8 9 the risk of death of CVD causes, mCA due to loss of the X chromosome was associated 10 with the risk of death of CAD causes, and mCA due loss of the Y chromosome was 11 associated with the risk of death of any causes.

Second, exploratory analyses suggest that carriers of mCAs were at higher risk of 12 13 incident STEMI and peripheral vascular disease: and for cancer survivors aged >65 14 years, at a higher risk of incident NSTEMI, stable angina, intracerebral hemorrhage, and subarachnoid hemorrhage. In comparison, a previous mCA study focusing on MI and 15 16 stroke did not find any significant associations when focusing on carriers of expanded mCAs, regardless of cancer status.<sup>20</sup> The current study suggests that any mCA carrier 17 status can be prognostic of several other CV phenotypes in cancer survivors. Previous 18 19 research looking at mutation driven CH have correlated mutations in DNMT3A and TET2 with chronic heart failure in patients with STEMI (n=485).<sup>35</sup> In another study 20 including approximately 50 000 samples with exome sequencing data, Zekavat et al.<sup>26</sup> 21 22 found that carriers of CHIP mutations had higher risks of peripheral artery disease.

Third, when considering cancer survivors, it is possible that cancer-directed treatments
 may have perpetuated the influence of mCA on outcomes.<sup>25</sup> However, our sub-analyses

medRxiv preprint doi: https://doi.org/10.1101/2022.08.20.22279019; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

which included a chemotherapy-by-mCA interaction term failed to reach statistical 1 2 significance, albeit a near 2-fold increased risk of death of CAD causes for mCA carriers. Previous work have supported the hypothesis that chemotherapy may lead to 3 clonal expansion of mutations in apotosis or DNA repair gens (TP53, PPM1D)<sup>25,36</sup>, and 4 5 that CHIP mutations caused by these genes could worsen the risk of atherosclerosis<sup>26</sup>. It 6 is possible that chemotherapy usage may not be well-captured in the current database. 7 Furthermore, without knowledge on tumor aggressiveness in the current database, it was not possible to exclude the presence of a selection bias where carriers of mCAs 8 9 may be at a more advanced stage of the disease or have a more aggressive tumor histology, which may make them more likely to undergo additional lines of 10 11 chemotherapy, which could have contributed to their risks of CVD. It will be critical to 12 evaluate whether cancer-directed treatments have an additive or synergistic influence 13 on mCAs. Further research will be needed to understand the impact of mCAs on CVD 14 outcomes following modern standards of care, such as treatment with immunecheckpoint inhibitors. In that scenario, mCA carriers may benefit from an in-depth 15 16 preventive cardiology approach prior to treatment where multi-disciplinary cardio-17 oncology care could mitigate such risks.

Fourth, we found that the effect of mCA on the risks of death of CVD and CAD causes, as well as of death of any cause was specific to previous smokers. This upholds the findings of a recent study which established strong causal associations between smoking and mCAs, and postulated that smoking may contribute to the selection of clones bearing somatic mutations.<sup>37</sup> Indeed, we found that cancer survivors who are carriers of mCAs may face added risks if they were previous smokers. Additional work is

required to better evaluate how smoking habits can impact mCAs and the downstream
 consequences of such mutations, especially in patients diagnosed with cancer.

Nevertheless, the generalizability of our findings may be limited as the influence of mCA was not consistent across all examined cancer types. This was not entirely unexpected given the heterogeneous biology of cancers included and distinct mechanisms of mCAs with respect to these cancers and treatments that patients received. Even so, the associations observed within this study may inform future studies focusing on the effect of mCA and the risks of death from CVD causes for specific cancer types.

9 Our study has additional limitations. First, our study did not consider CHIP mutations. 10 While the association of CHIP mutations with CVD has been established, it has not been 11 formally tested in patients diagnosed exclusively with non-hematologic cancer. There is reason to believe that carriers of CHIP mutations in addition to being diagnosed with 12 cancer may face higher risks of CVD. In addition, the synergistic effect of both mCA and 13 14 CHIP mutation carriers amongst cancer survivors will be of interest to explore in future studies. Second, It has been established that detectable hematopoietic loss of the X and 15 16 Y chromosomes increase with age, with more age-related pathologies in older individuals than in younger individuals.<sup>38,39</sup> Unexpectedly, the association between the 17 mosaic loss of the Y chromosome and death of CVD causes was not significant in the 18 current analysis that focused on cancer survivors. The non-significant association may 19 have been related to mosaic loss of the Y chromosome definition used, where a larger 20 21 percentage threshold of blood cells lacking chromosome Y may be more relevant. For example, a recent analysis found that regardless of their cancer status, men with mosaic 22 loss of the Y chromosome in 40% or more of leukocytes displayed a 31% increased risk 23 24 of dying from any disease related to the circulatory system based on survival data from

medRxiv preprint doi: https://doi.org/10.1101/2022.08.20.22279019; this version posted August 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

the UK Biobank.<sup>39</sup> In contrast, the relative risk per 1% increase of detectable loss of Y 1 2 chromosome and the risk of death from CVD causes was more subdued (HR: 1.0054, P=0.001).<sup>39</sup> We did also note that mosaic loss of the Y chromosome was rather 3 impactful for cancer-specific mortality, which may be relevant in considering the 4 significant association found between loss of the Y chromosome and death of any 5 cause. Third, mCA status was evaluated only at study entry. Reasonably, clones 6 7 carrying a mCA may undergo rapid changes following various environmental exposures (e.g. smoking, chemotherapy). Under this premise, serial measurements of mCA may 8 9 better help inform the dose-response effect of such factors and mCA. Finally, while 10 adjustment was made for chemotherapy and radiotherapy treatment, some individuals 11 may have undergone such treatments in the outpatient setting, which would not have 12 been properly captured using inpatient procedural codes.

In conclusion, our study showed that mCAs are associated with higher risks of death of CAD causes among cancer survivors. mCAs were also associated with higher risks of death from cancer and death of any cause. Notably, autosomal mCAs appeared to be driving most of the observed associations. Future studies may focus on specific cancer types and their treatments to better ascertain the effect of mCA on the risk of CVD and evaluate if they constitute a useful biomarker in the management of cancer survivors.

19

#### 20 **METHODS**

21 Study samples

The UK Biobank is a large population-based cohort that includes over 500,000 participants aged between 40-70 years old, recruited from 2006 to 2010.<sup>40</sup> Baseline interviews regarding their medical history and environmental exposures were conducted

in the UK across 22 assessment centers where blood samples for genotyping were also
obtained and blood analysis performed. Additional health outcome data, including
diagnoses of cancer and CVD, have been linked via UK national registries and hospital
records managed by the NHS, and genome-wide genotyping of blood-derived DNA was
performed by the UK Biobank using 2 genotyping arrays sharing 95% of marker content:
Applied Biosystems UK BiLEVE Axiom Array and Applied Biosystems UK Biobank
Axiom Array, both by Affymetrix.<sup>41</sup>

8 Determination of mosaic chromosomal alterations

Previously, Loh et al.<sup>20</sup> identified mosaic chromosomal alteration in 487 409 genotyped 9 individuals. As previously described<sup>19,20</sup>, mCAs were determined from genotype 10 11 intensities log<sub>2</sub>R ratio (LRR) and B-allele frequency (BAF) values, which were used to estimate the total and relative allelic intensities, respectively. Re-phasing was conducted 12 using Eagle2<sup>42</sup> and mCA calling was performed by leveraging long-range phase 13 14 information searching for allelic imbalances between maternal and paternal allelic 15 fractions across contiguous genomic segments. For the purpose of our study, mCA calls were obtained from dataset Return 3094 from the UK Biobank application 19808.<sup>20,42</sup> 16 17 From the genetic data of the UK Biobank, 479 435 individuals who passed the sample guality control criteria, including genotypic-phenotypic sex concordance, and without first 18 19 or second-degree relatives in the dataset were considered (Figure 3). Of those, we identified 48 919 participants with a diagnosis of cancer before or after the baseline 20 21 assessment visit based on the cancer register, using ICD-9 and ICD-10 diagnostic 22 codes for bladder, larynx, prostate, corpus uteri, rectum, breast, kidney, non-Hodgkin lymphoma, melanoma of the skin, or lung cancer (Suppl. Materials, sTable 14). These 23

specific cancer types were selected based on a previous publication which identified the
 top 10 cancer sites with the largest percentage of deaths attributed to CVD.<sup>34</sup>

3 Exposure and clinical outcomes

The exposure of interest was the presence of a mCA of any type, which was classified 4 as  $\geq 1$  or none. mCAs were also categorized as autosomal mCAs, loss of the X 5 chromosome, loss of the Y chromosome, and expanded mCAs (defined as mCAs 6 present in at least 10% of peripheral leukocyte DNA indicative of clonal expansion<sup>43</sup>). 7 The study primary endpoints consisted of death of CVD causes, death of CAD causes, 8 death from cancer, and death of any cause based on ICD-10 codes for primary cause of 9 10 death from the death register records (**Suppl. Materials, sTable 15**). For each endpoint, 11 the time to death was calculated from the date of the assessment visit at the time of recruitment into the UK Biobank (baseline) if patients' cancer diagnosis occurred before 12 baseline, and alternatively, from the date of cancer diagnosis if the cancer diagnosis 13 14 occurred after baseline. The number of days between a patient's cancer diagnosis date 15 and baseline was recorded, and it was set as 0 if the cancer diagnosis occurred after 16 baseline. For individuals who were not deceased, the end of follow-up was the last date 17 of death registered based on participant's country of enrolment (i.e., 2021-03-30 for England, 2021-03-23 for Scotland and 2021-03-16 for Wales). 18

Other exploratory endpoints included various incident CV phenotypes<sup>44</sup> recorded after patients' cancer diagnosis date (**Suppl. Materials, sTable 15**). For these endpoints, the time to the event (i.e., incident CV event of interest or death of CVD causes) was calculated from the date of cancer diagnosis. For those who did not experience any incident CV events, censor date was set to the date of death of non-CVD causes, or the last hospitalization date known for each patient.

#### 1 Statistical analyses

2 In our primary analyses focusing on the association between mCAs and death of CVD causes, CAD causes, from cancer, and death of any cause, Cox proportional hazards 3 regression models were used, adjusting for age at baseline, sex, smoking status, 4 5 treatment with chemotherapy and/or radiotherapy, the number of days between cancer diagnosis and date of baseline, and principal components for genetic ancestry (PC, 1-6 7 10). An mCA-by-cancer status interaction term was also assessed with respect to each of the primary endpoints in the overall population including individuals without any 8 9 history of cancer (n=479 435). We further examined the associations of mCA types 10 (autosomal mCAs, mosaic loss of the Y chromosome, mosaic loss of the X 11 chromosome, and expanded mCAs) on the primary endpoints of interest. Sensitivity 12 analyses considered the additional adjustment for hypertension and body mass index. 13 Cox regression models were also used for exploratory analyses of incident CV 14 phenotypes. Sub-group analyses were conducted according to cancer types, smoking 15 status, treatment with chemotherapy, and age at baseline dichotomized at 65 years. All 16 analyses were performed using the survival package in R (version 4.1.2, Bird Hippie). All analytical and summary reports were produced with gtsummary (version 1.6.1).<sup>45</sup> 17

### **Figure Legends**

**Table 1.** Summary descriptives of patients with a cancer diagnosis according to mosaic chromosomal alterations status. mCA: mosaic chromosomal alteration; IQR: interquartile range; SD: standard deviation; CVD: cardiovascular disease; CAD: coronary artery disease

**Figure 1.** Multivariable Cox regression models evaluating the effect of mosaic chromosomal alterations on death of cardiovascular disease causes, of coronary artery disease causes, from cancer, and death of any cause. All models are adjusted for age at baseline, sex, smoking status, chemotherapy, radiotherapy, number of days between the date of recruitment and the date of cancer diagnosis, and principal components 1 to 10. CAD: coronary artery disease, CI: confidence interval, CVD: cardiovascular disease, HR: hazard ratio, mCA: mosaic chromosomal alterations, Ref.: referent category (1.0)

**Figure 2.** Multivariable Cox regression models evaluating the effect of mosaic chromosomal alterations on incident cardiovascular phenotypes. All models are adjusted for age at baseline, sex, smoking status, chemotherapy, radiotherapy, number of days between the date of recruitment and the date of cancer diagnosis, and principal components 1 to 10. CVD: cardiovascular disease, CI: confidence interval, HR: hazard ratio, mCA: mosaic chromosomal alteration, MI: myocardial infarction, NSTEMI: non-ST-elevation myocardial infarction, STEMI: ST-elevation myocardial infarction, TIA: transient ischemic attack.

Figure 3. Visual representation of the study flow.

**sFigure 1.** Visual depiction of the proportion of patients with at least 1 mosaic chromosomal alteration in the overall cohort (A), of the proportion of patients with at least one mosaic chromosomal alteration stratified according to age groups (B), and of the proportion of patients with at least one mosaic chromosomal alteration stratified according to cancer types (C). mCA: mosaic chromosomal alteration.

# References

- 1 Coleman, M. P. *et al.* EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. *Annals of oncology : official journal of the European Society for Medical Oncology* **14 Suppl 5**, v128-149, doi:10.1093/annonc/mdg756 (2003).
- Bluethmann, S. M., Mariotto, A. B. & Rowland, J. H. Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. *Cancer Epidemiology, Biomarkers & Prevention* 25, 1029-1036, doi:10.1158/1055-9965.EPI-16-0133 (2016).
- 3 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. *CA: A Cancer Journal for Clinicians* **66**, 7-30, doi:<u>https://doi.org/10.3322/caac.21332</u> (2016).
- 4 Armenian, S. H. *et al.* Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **34**, 1122-1130, doi:10.1200/jco.2015.64.0409 (2016).
- 5 Haugnes, H. S. *et al.* Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **28**, 4649-4657, doi:10.1200/jco.2010.29.9362 (2010).
- 6 Emery, J. *et al.* Management of common clinical problems experienced by survivors of cancer. *Lancet (London, England)* **399**, 1537-1550, doi:10.1016/s0140-6736(22)00242-2 (2022).
- 7 Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. *The Lancet* **391**, 933, doi:10.1016/S0140-6736(18)30533-6 (2018).
- 8 Lamberg, M. *et al.* Next Generation Risk Markers in Preventive Cardio-oncology. *Current Atherosclerosis Reports*, doi:10.1007/s11883-022-01021-x (2022).
- 9 Khoury, J. D. *et al.* The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia* **36**, 1703-1719, doi:10.1038/s41375-022-01613-1 (2022).
- 10 Busque, L. *et al.* Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nat Genet* **44**, 1179-1181, doi:10.1038/ng.2413 (2012).
- 11 Jaiswal, S. *et al.* Age-related clonal hematopoiesis associated with adverse outcomes. *The New England journal of medicine* **371**, 2488-2498, doi:10.1056/NEJMoa1408617 (2014).
- 12 Genovese, G. *et al.* Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. *New England Journal of Medicine* **371**, 2477-2487, doi:10.1056/NEJMoa1409405 (2014).
- 13 Xie, M. *et al.* Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med* **20**, 1472-1478, doi:10.1038/nm.3733 (2014).
- 14 McKerrell, T. *et al.* Leukemia-associated somatic mutations drive distinct patterns of agerelated clonal hemopoiesis. *Cell Rep* **10**, 1239-1245, doi:10.1016/j.celrep.2015.02.005 (2015).
- 15 Steensma, D. P. *et al.* Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood* **126**, 9-16, doi:10.1182/blood-2015-03-631747 (2015).
- 16 Laurie, C. C. *et al.* Detectable clonal mosaicism from birth to old age and its relationship to cancer. *Nat Genet* **44**, 642-650, doi:10.1038/ng.2271 (2012).

- 17 Jacobs, K. B. *et al.* Detectable clonal mosaicism and its relationship to aging and cancer. *Nat Genet* **44**, 651-658, doi:10.1038/ng.2270 (2012).
- 18 Forsberg, L. A. *et al.* Age-related somatic structural changes in the nuclear genome of human blood cells. *American journal of human genetics* **90**, 217-228, doi:10.1016/j.ajhg.2011.12.009 (2012).
- 19 Loh, P.-R. *et al.* Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. *Nature* **559**, 350-355, doi:10.1038/s41586-018-0321-x (2018).
- 20 Loh, P.-R., Genovese, G. & McCarroll, S. A. Monogenic and polygenic inheritance become instruments for clonal selection. *Nature* **584**, 136-141, doi:10.1038/s41586-020-2430-6 (2020).
- 21 Jaiswal, S. *et al.* Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. *The New England journal of medicine* **377**, 111-121, doi:10.1056/NEJMoa1701719 (2017).
- 22 Bick, A. G. *et al.* Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis. *Circulation* **141**, 124-131, doi:10.1161/circulationaha.119.044362 (2020).
- 23 Honigberg, M. C. *et al.* Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. *Circulation* **143**, 410-423, doi:10.1161/CIRCULATIONAHA.120.051775 (2021).
- 24 Busque, L. *et al.* High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. *Blood Advances* **4**, 2430-2438, doi:10.1182/bloodadvances.2019000770 (2020).
- 25 Coombs, C. C. *et al.* Therapy-Related Clonal Hematopoiesis in Patients with Nonhematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. *Cell stem cell* **21**, 374-382.e374, doi:10.1016/j.stem.2017.07.010 (2017).
- 26 Zekavat, S. M. *et al.* TP53-mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease. *medRxiv*, 2021.2008.2022.21262430, doi:10.1101/2021.08.22.21262430 (2022).
- 27 Lin, S. H. *et al.* Incident disease associations with mosaic chromosomal alterations on autosomes, X and Y chromosomes: insights from a phenome-wide association study in the UK Biobank. *Cell Biosci* **11**, 143, doi:10.1186/s13578-021-00651-z (2021).
- 28 Forsberg, L. A. *et al.* Mosaic loss of chromosome Y in leukocytes matters. *Nat Genet* **51**, 4-7, doi:10.1038/s41588-018-0267-9 (2019).
- 29 Loftfield, E. *et al.* Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. *Scientific Reports* **8**, 12316, doi:10.1038/s41598-018-30759-1 (2018).
- 30 Forsberg, L. A. *et al.* Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. *Nature Genetics* **46**, 624-628, doi:10.1038/ng.2966 (2014).
- 31 Dumanski, J. P. *et al.* Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. *American journal of human genetics* **98**, 1208-1219, doi:10.1016/j.ajhg.2016.05.014 (2016).
- 32 Persani, L. *et al.* Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. *Journal of autoimmunity* **38**, J193-196, doi:10.1016/j.jaut.2011.11.011 (2012).
- 33 Haitjema, S. *et al.* Loss of Y Chromosome in Blood Is Associated With Major Cardiovascular Events During Follow-Up in Men After Carotid Endarterectomy. *Circulation. Cardiovascular genetics* **10**, e001544, doi:10.1161/circgenetics.116.001544 (2017).

- 34 Sturgeon, K. M. *et al.* A population-based study of cardiovascular disease mortality risk in US cancer patients. *European Heart Journal* **40**, 3889-3897, doi:10.1093/eurheartj/ehz766 (2019).
- 35 Wang, S. *et al.* Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. *EBioMedicine* **78**, 103964, doi:10.1016/j.ebiom.2022.103964 (2022).
- 36 Bolton, K. L. *et al.* Cancer therapy shapes the fitness landscape of clonal hematopoiesis. *Nature Genetics* **52**, 1219-1226, doi:10.1038/s41588-020-00710-0 (2020).
- 37 Levin, M. G. *et al.* Genetics of smoking and risk of clonal hematopoiesis. *Scientific Reports* **12**, 7248, doi:10.1038/s41598-022-09604-z (2022).
- 38 Machiela, M. J. *et al.* Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. *Nature Communications* **7**, 11843, doi:10.1038/ncomms11843 (2016).
- 39 Sano, S. *et al.* Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. *Science* **377**, 292-297, doi:doi:10.1126/science.abn3100 (2022).
- 40 Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine* **12**, e1001779, doi:10.1371/journal.pmed.1001779 (2015).
- 41 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 42 Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nature Genetics* **48**, 1443-1448, doi:10.1038/ng.3679 (2016).
- 43 Zekavat, S. M. *et al.* Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. *Nature Medicine* **27**, 1012-1024, doi:10.1038/s41591-021-01371-0 (2021).
- 44 Wan, E. Y. F. *et al.* Blood Pressure and Risk of Cardiovascular Disease in UK Biobank. *Hypertension* **77**, 367-375, doi:10.1161/HYPERTENSIONAHA.120.16138 (2021).
- 45 Sjoberg DD, Whiting K, Curry M, Lavery JA & J, L. Reproducible summary tables with the gtsummary package. *The R Journal* **13**, 570-580 (2021).

**Table 1.** Summary descriptives of patients with a cancer diagnosis stratified according to mosaic chromosomal alteration status.

Characteristic	Ν	<b>Overall</b> , N = 48,919 <sup>7</sup>	<b>No mCA</b> , N = 38,849 <sup>1</sup>	<b>Any mCA</b> , N = 10,070 <sup>1</sup>	p-value <sup>2</sup>
Age at bsl	48,919				<0.001
Ν		48,919	38,849	10,070	
N missing		0	0	0	
Mean (SD)		60 (7)	60 (7)	63 (5)	
Median (IQR)		62 (56, 65)	61 (55, 65)	64 (61, 67)	
Range		40, 71	40, 70	40, 71	
Men	48,919	22,403 (45.8%)	14,989 (38.6%)	7,414 (73.6%)	<0.001
Smoking status	48,624				<0.001
Never smoker		23,865 (49.1%)	19,888 (51.5%)	3,977 (39.7%)	
Previous smoker		19,274 (39.6%)	14,755 (38.2%)	4,519 (45.1%)	
Current smoker		5,485 (11.3%)	3,970 (10.3%)	1,515 (15.1%)	
Unknown		295	236	59	
Prevalent CVD	48,919	43,342 (88.6%)	34,805 (89.6%)	8,537 (84.8%)	<0.001
Bladder cancer	48,919	1,743 (3.6%)	1,191 (3.1%)	552 (5.5%)	<0.001
Larynx cancer	48,919	375 (0.8%)	245 (0.6%)	130 (1.3%)	<0.001

Characteristic	Ν	<b>Overall</b> , N = 48,919 <sup>7</sup>	<b>No mCA</b> , N = 38,849 <sup>1</sup>	<b>Any mCA</b> , N = 10,070 <sup>1</sup>	p-value <sup>2</sup>
Corpus Uteri	48,919	2,331 (4.8%)	2,108 (5.4%)	223 (2.2%)	<0.001
Prostate cancer	48,919	13,274 (27.1%)	8,970 (23.1%)	4,304 (42.7%)	<0.001
Breast cancer	48,919	17,304 (35.4%)	15,678 (40.4%)	1,626 (16.1%)	<0.001
Rectal cancer	48,919	2,268 (4.6%)	1,731 (4.5%)	537 (5.3%)	<0.001
Kidney cancer	48,919	1,910 (3.9%)	1,472 (3.8%)	438 (4.3%)	0.010
Non-Hodgkin lymphoma	48,919	3,038 (6.2%)	2,189 (5.6%)	849 (8.4%)	<0.001
Melanoma	48,919	4,912 (10.0%)	4,031 (10.4%)	881 (8.7%)	<0.001
Lung cancer	48,919	4,215 (8.6%)	3,074 (7.9%)	1,141 (11.3%)	<0.001
Chemotherapy	48,919				<0.001
None		37,512 (76.7%)	29,610 (76.2%)	7,902 (78.5%)	
Yes		11,407 (23.3%)	9,239 (23.8%)	2,168 (21.5%)	
Radiotherapy	48,919				0.036
None		45,846 (93.7%)	36,454 (93.8%)	9,392 (93.3%)	
Yes		3,073 (6.3%)	2,395 (6.2%)	678 (6.7%)	
Prevalent hypertension	48,919	6,077 (12.4%)	4,569 (11.8%)	1,508 (15.0%)	<0.001
Autosomal mCA	48,919				<0.001

Characteristic	Ν	<b>Overall</b> , N = 48,919 <sup>7</sup>	<b>No mCA</b> , N = 38,849 <sup>1</sup>	<b>Any mCA</b> , N = 10,070 <sup>7</sup>	p-value <sup>2</sup>
Ref.		46,487 (95.0%)	38,849 (100.0%)	7,638 (75.8%)	
Autosomal		2,432 (5.0%)	0 (0.0%)	2,432 (24.2%)	
Loss of X	48,919				<0.001
Ref.		47,278 (96.6%)	38,849 (100.0%)	8,429 (83.7%)	
Loss of X		1,641 (3.4%)	0 (0.0%)	1,641 (16.3%)	
Loss of Y	48,919				<0.001
Ref.		42,361 (86.6%)	38,849 (100.0%)	3,512 (34.9%)	
Loss of Y		6,558 (13.4%)	0 (0.0%)	6,558 (65.1%)	
Expanded mCA	48,919				<0.001
Ref.		47,009 (96.1%)	38,849 (100.0%)	8,160 (81.0%)	
Expanded mCA		1,910 (3.9%)	0 (0.0%)	1,910 (19.0%)	
Death of CVD causes	48,919	813 (1.7%)	550 (1.4%)	263 (2.6%)	<0.001
Death of CAD causes	48,919	368 (0.8%)	226 (0.6%)	142 (1.4%)	<0.001
Death from cancer	48,919	8,433 (17.2%)	6,254 (16.1%)	2,179 (21.6%)	<0.001
Death of any cause <sup>1</sup> n (%) <sup>2</sup> Wilcoxon rank sum test:	48,919 Pearson's C	10,632 (21.7%)	7,785 (20.0%)	2,847 (28.3%)	<0.001

bsl.: baseline, CAD: coronary artery disease, CVD: cardiovascular disease, IQR: interquartile range, mCA: mosaic chromosomal alteration, Ref.: referent category, SD: standard deviation



Incident CV phenotypes		<u>N</u> events	<u>Nb of events</u> for mCA	<u>mCA vs. none</u> HR (95% CI)	<u>P value</u>
				,	
Subarachnoid hemorrhage	¦ ⊦¦∎i	862	271	1.136 (0.970, 1.324)	0.104
STEMI	∮ <b>₩</b>	940	309	1.185 (1.025, 1.369)	0.022
Intracerebral hemorrhage	l <mark>¦ ∎</mark> l	975	303	1.125 (0.970, 1.300)	) 0.110
Stable angina	┝┋╋╌┤	1 039	322	1.097 (0.950, 1.261)	0.195
Heart failure	⊢ <mark>∔</mark> ∎−-1	1 108	322	1.051 (0.916, 1.207)	0.477
Unstable angina	╞╌┦	1 412	411	1.043 (0.924, 1.179)	0.495
NSTEMI	i ŀ <mark>i-</mark> ⊞1	1 464	445	1.087 (0.970, 1.223)	0.169
Ischemic stroke	┆ ┝╬╋╌┤	1 570	460	1.054 (0.939, 1.183)	0.370
Peripheral vascular disease	∎	1 643	504	1.168 (1.044, 1.307)	0.007
Stroke	┝╪┳╌┥	1 763	511	1.073 (0.960, 1.197)	0.207
Myocardial infarction	₽ ₽ <b>₽</b> ₽₽	2 452	735	1.049 (0.960, 1.150)	0.304
Transient ischemic attack	⊢∰-1	2 517	698	0.990 (0.900, 1.083)	0.785
Asthma	⊦₩	3 898	811	1.026 (0.945, 1.114)	0.544
Ischemic heart disease	H∰-1	4 339	1 160	0.990 (0.926, 1.068)	0.880
Arrhythmia and conduction	⊦∰⊒-1	4 871	1 364	1.019 (0.950, 1.089)	0.578
CVD	H	5 076	1 362	1.013 (0.948, 1.082)	0.703
_	Ref.	2			
	HR (95% CI)				

